Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAMUSCULARGeneric

PLENAXIS

ABARELIX

Standard Dose
100MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary

Approval overview PLENAXIS is listed in Drugs@FDA under application 021320 (NDA).

Review priority: PRIORITY Marketing status: Discontinued Active ingredient ABARELIX Form and strength POWDER;INTRAMUSCULAR - 100MG/VIAL Sponsor SPECIALITY EUROPEAN Submission history Latest submission status date: 2005-09-08 00:00:00.

Structured Monograph

Clinical summary

Approval overview PLENAXIS is listed in Drugs@FDA under application 021320 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient ABARELIX Form and strength POWDER;INTRAMUSCULAR - 100MG/VIAL Sponsor SPECIALITY EUROPEAN Submission history Latest submission status date: 2005-09-08 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.